Journal
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
Volume 23, Issue 12, Pages 732-740Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.5435/JAAOS-D-14-00223
Keywords
-
Categories
Funding
- Biomet
- DePuy
- Stryker
- Zimmer
Ask authors/readers for more resources
Perioperative blood loss is a significant concern for patients undergoing total joint arthroplasty. A growing body of evidence has shown tranexamic acid (TXA) to be effective in decreasing perioperative blood loss and transfusion requirements in both primary and revision hip and knee arthroplasty. TXA is a synthetic drug that limits blood loss through inhibition of fibrinolysis and clot degradation. Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective. Further investigation is required to determine the optimal dose and dosing regimens; however, evidence exists to recommend an initial intravenous dose be given before beginning the procedure, with at least one additional intravenous dose administered postoperatively. Additionally, topical TXA doses >2 g appear to be more efficacious than lower doses. Finally, relatively few adverse reactions have been reported in arthroplasty patients, and no study to date has demonstrated an increased risk of symptomatic venous thromboembolic events in this patient population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available